$MGNX
MACROGENICS INC Stock $mgnx

$mgnx Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000112534524000060 Filed on March 07, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$9.104M	$10.72M	$58.75M
YoY Change	-62.83%	-85.33%	-61.33%
Cost Of Revenue	$270.0K	$163.0K	$8.222M
YoY Change	138.94%	-90.9%	145.36%
Gross Profit	$8.834M	$10.56M	$50.53M
YoY Change	-63.77%	-85.2%	-66.0%
Gross Profit Margin	97.03%	98.48%	86.0%
Selling, General & Admin	$14.71M	$12.56M	$52.19M
YoY Change	8.74%	-8.13%	-11.47%
% of Gross Profit	166.5%	118.97%	103.29%
Research & Development	$46.03M	$47.35M	$166.6M
YoY Change	0.34%	3.72%	-19.54%
% of Gross Profit	521.04%	448.53%	329.69%
Depreciation & Amortization	$1.841M	$1.900M	$9.645M
YoY Change	-38.28%	-41.19%	-18.71%
% of Gross Profit	20.84%	18.0%	19.09%
Operating Expenses	$46.03M	$59.91M	$218.8M
YoY Change	0.34%	0.99%	5.67%
Operating Profit	-$53.75M	-$49.35M	-$168.2M
YoY Change	39.88%	-511.87%	38.57%
Interest Expense	$1.133M	-$1.000K	$2.569M
YoY Change	-272.71%		51.12%
% of Operating Profit
Other Income/Expense, Net	$2.693M	$3.282M	$5.686M
YoY Change	150.98%	300.73%	242.53%
Pretax Income	-$52.19M	-$46.07M	-$9.059M
YoY Change	37.31%	-459.89%	-92.44%
Income Tax			$0.00
% Of Pretax Income
Net Earnings	-$52.19M	-$46.07M	-$9.058M
YoY Change	37.31%	-459.88%	-92.44%
Net Earnings / Revenue	-573.26%	-429.78%	-15.42%
Basic Earnings Per Share	-$0.84		-$0.15
Diluted Earnings Per Share	-$0.84	-$0.74	-$0.15
COMMON SHARES
Basic Shares Outstanding	62.43M shares	62.03M shares	61.93M shares
Diluted Shares Outstanding	62.29M shares		61.93M shares

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$184.2M	$229.8M	$229.8M
YoY Change	-23.76%	48.89%	48.89%
Cash & Equivalents	$80.36M	$101.0M	$101.0M
Short-Term Investments	$103.9M	$128.8M	$128.8M
Other Short-Term Assets	$9.871M	$9.946M	$9.946M
YoY Change	1.57%	-2.12%	-2.12%
Inventory	$1.248M	$1.221M	$1.221M
Prepaid Expenses		$9.946M
Receivables	$7.219M	$10.37M	$10.37M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$202.6M	$251.3M	$251.3M
YoY Change	-29.89%	13.12%	13.12%
LONG-TERM ASSETS
Property, Plant & Equipment	$21.30M	$45.69M	$45.69M
YoY Change	-20.49%	54.5%	-19.71%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$1.185M	$1.386M	$1.386M
YoY Change	-14.01%	0.58%	0.58%
Total Long-Term Assets	$45.71M	$47.08M	$47.08M
YoY Change	-16.21%	-19.23%	-19.23%
TOTAL ASSETS
Total Short-Term Assets	$202.6M	$251.3M	$251.3M
Total Long-Term Assets	$45.71M	$47.08M	$47.08M
Total Assets	$248.3M	$298.4M	$298.4M
YoY Change	-27.72%	6.4%	6.4%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$10.69M	$6.443M	$6.443M
YoY Change	184.49%	31.52%	31.52%
Accrued Expenses	$18.15M	$28.01M	$28.01M
YoY Change	-35.62%	-3.39%	-16.93%
Deferred Revenue	$22.84M	$21.65M
YoY Change	146.91%	116.77%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$55.76M	$56.11M	$56.11M
YoY Change	22.25%	15.42%	15.42%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$258.0K	$89.70M	$89.70M
YoY Change	0.0%	34666.28%	-0.16%
Total Long-Term Liabilities	$258.0K	$89.70M	$89.70M
YoY Change	0.0%	34666.28%	-0.16%
TOTAL LIABILITIES
Total Short-Term Liabilities	$55.76M	$56.11M	$56.11M
Total Long-Term Liabilities	$258.0K	$89.70M	$89.70M
Total Liabilities	$142.1M	$145.8M	$145.8M
YoY Change	-39.32%	5.31%	5.31%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.155B	-$1.103B
YoY Change	2.05%	0.83%
Common Stock	$1.261B	$1.255B
YoY Change	1.63%	1.59%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$106.2M	$152.6M	$152.6M
YoY Change
Total Liabilities & Shareholders Equity	$248.3M	$298.4M	$298.4M
YoY Change	-27.72%	6.4%	6.4%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$52.19M	-$46.07M	-$9.058M
YoY Change	37.31%	-459.88%	-92.44%
Depreciation, Depletion And Amortization	$1.841M	$1.900M	$9.645M
YoY Change	-38.28%	-41.19%	-18.71%
Cash From Operating Activities	-$45.64M	-$28.04M	-$78.21M
YoY Change	255.67%	-195.62%	-10.07%
INVESTING ACTIVITIES
Capital Expenditures	$1.459M	$620.0K	$1.764M
YoY Change	306.41%	57.76%	-51.31%
Acquisitions
YoY Change
Other Investing Activities	$26.25M	$39.44M	-$78.32M
YoY Change	-7.74%	-831.08%	-205.36%
Cash From Investing Activities	$24.79M	$38.82M	-$80.08M
YoY Change	-11.75%	-770.73%	-213.25%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$863.0K
YoY Change			-20.46%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$248.0K	273.0K	150.4M
YoY Change	-99.75%	-79.91%	8963.35%
NET CHANGE
Cash From Operating Activities	-$45.64M	-28.04M	-78.21M
Cash From Investing Activities	$24.79M	38.82M	-80.08M
Cash From Financing Activities	$248.0K	273.0K	150.4M
Net Change In Cash	-$20.60M	11.06M	-7.928M
YoY Change	-117.85%	-55.57%	-45.64%
FREE CASH FLOW
Cash From Operating Activities	-$45.64M	-$28.04M	-$78.21M
Capital Expenditures	$1.459M	$620.0K	$1.764M
Free Cash Flow	-$47.10M	-$28.66M	-$79.97M
YoY Change	257.05%	-199.07%	-11.72%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-36112
CY2023	dei	Entity Registrant Name EntityRegistrantName	MACROGENICS, INC.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	06-1591613
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	9704 Medical Center Drive
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Rockville
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	MD
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	20850
CY2023	dei	City Area Code CityAreaCode	301
CY2023	dei	Local Phone Number LocalPhoneNumber	251-5172
CY2023	dei	Trading Symbol TradingSymbol	MGNX
CY2023	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	false
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2021	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	0	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	45836000	usd
CY2023	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-230000	usd
CY2022	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	14045000	usd
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001125345
CY2023	dei	Security12b Title Security12bTitle	Common Stock, par value $0.01 per share
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023Q4	dei	Entity Public Float EntityPublicFloat	322500000	usd
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	62432013	shares
CY2023Q4	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2023Q4	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2023	dei	Auditor Firm AuditorFirmId	42
CY2023	dei	Auditor Name AuditorName	Ernst & Young LLP
CY2023	dei	Auditor Location AuditorLocation	Tysons, Virginia
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	100956000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	108884000	usd
CY2023Q4	us-gaap	Investments Investments	128849000	usd
CY2022Q4	us-gaap	Investments Investments	45462000	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	10367000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	56222000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	1221000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	1451000	usd
CY2023Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	9946000	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	10161000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	251339000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	222180000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	21847000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	29575000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	23846000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	27335000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1386000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1378000	usd
CY2023Q4	us-gaap	Assets Assets	298418000	usd
CY2022Q4	us-gaap	Assets Assets	280468000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	6443000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	4899000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	24239000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	28998000	usd
CY2023Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	21651000	usd
CY2022Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	9988000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3775000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	4726000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	56108000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	48611000	usd
CY2023Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	59243000	usd
CY2022Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	59480000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	30196000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	30106000	usd
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	258000	usd
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	258000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	145805000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	138455000	usd
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	125000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	125000000	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	62070627	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	61701467	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	621000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	617000	usd
CY2023Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1254750000	usd
CY2022Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1235095000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-6000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-5000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1102752000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1093694000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	152613000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	142013000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	298418000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	280468000	usd
CY2023	us-gaap	Revenues Revenues	58749000	usd
CY2022	us-gaap	Revenues Revenues	151941000	usd
CY2021	us-gaap	Revenues Revenues	77447000	usd
CY2023	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	619000	usd
CY2022	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	3351000	usd
CY2021	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	2651000	usd
CY2023	mgnx	Cost Of Manufacturing Services CostOfManufacturingServices	7603000	usd
CY2022	mgnx	Cost Of Manufacturing Services CostOfManufacturingServices	4033000	usd
CY2021	mgnx	Cost Of Manufacturing Services CostOfManufacturingServices	0	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	166583000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	207026000	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	214577000	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	52188000	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	58949000	usd
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	63014000	usd
CY2023	us-gaap	Costs And Expenses CostsAndExpenses	226993000	usd
CY2022	us-gaap	Costs And Expenses CostsAndExpenses	273359000	usd
CY2021	us-gaap	Costs And Expenses CostsAndExpenses	280242000	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-168244000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-121418000	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-202795000	usd
CY2023	mgnx	Gain On Royalty Monetization Arrangement GainOnRoyaltyMonetizationArrangement	150930000	usd
CY2022	mgnx	Gain On Royalty Monetization Arrangement GainOnRoyaltyMonetizationArrangement	0	usd
CY2021	mgnx	Gain On Royalty Monetization Arrangement GainOnRoyaltyMonetizationArrangement	0	usd
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	9686000	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1660000	usd
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	680000	usd
CY2023	us-gaap	Interest Expense InterestExpense	1430000	usd
CY2022	us-gaap	Interest Expense InterestExpense	0	usd
CY2021	us-gaap	Interest Expense InterestExpense	0	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-9058000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-119758000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-202115000	usd
CY2023	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-1000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	56000	usd
CY2021	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-54000	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-9059000	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-119702000	usd
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-202169000	usd
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.15
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.15
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.95
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.95
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.37
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.37
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	61929198	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	61433124	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	59944717	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	59944717	shares
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	295884000	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	23126000	usd
CY2021	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	117818000	usd
CY2021	mgnx	Stock Issued During Period Value Stock Plan Activity StockIssuedDuringPeriodValueStockPlanActivity	4959000	usd
CY2021	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-54000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-202115000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	239618000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	20438000	usd
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	1085000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	142013000	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	18373000	usd
CY2023	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	1039000	usd
CY2023	mgnx	Stock Issued During Period Value Stock Plan Activity StockIssuedDuringPeriodValueStockPlanActivity	247000	usd
CY2023	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-1000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-9058000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	152613000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-9058000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-119758000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-202115000	usd
CY2023	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	9645000	usd
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	11865000	usd
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	11258000	usd
CY2023	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	5004000	usd
CY2022	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-403000	usd
CY2021	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-1607000	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	18373000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	20438000	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	23126000	usd
CY2023	mgnx	Gain On Royalty Monetization Arrangement GainOnRoyaltyMonetizationArrangement	150930000	usd
CY2022	mgnx	Gain On Royalty Monetization Arrangement GainOnRoyaltyMonetizationArrangement	0	usd
CY2021	mgnx	Gain On Royalty Monetization Arrangement GainOnRoyaltyMonetizationArrangement	0	usd
CY2023	mgnx	Non Cash Interest Expense Recognized NonCashInterestExpenseRecognized	1430000	usd
CY2022	mgnx	Non Cash Interest Expense Recognized NonCashInterestExpenseRecognized	0	usd
CY2021	mgnx	Non Cash Interest Expense Recognized NonCashInterestExpenseRecognized	0	usd
CY2023	mgnx	Operating Lease Noncash Expense OperatingLeaseNoncashExpense	3489000	usd
CY2022	mgnx	Operating Lease Noncash Expense OperatingLeaseNoncashExpense	3341000	usd
CY2021	mgnx	Operating Lease Noncash Expense OperatingLeaseNoncashExpense	2690000	usd
CY2023	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-423000	usd
CY2022	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-2882000	usd
CY2021	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-2035000	usd
CY2023	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	-111000	usd
CY2022	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	0	usd
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-45855000	usd
CY2023	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-215000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-11009000	usd
CY2021	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	4188000	usd
CY2021	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-3225000	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1281000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-10860000	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	7125000	usd
CY2023	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-4823000	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-4638000	usd
CY2021	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-607000	usd
CY2023	mgnx	Increase Decrease In Lease Liabilities IncreaseDecreaseInLeaseLiabilities	-861000	usd
CY2022	mgnx	Increase Decrease In Lease Liabilities IncreaseDecreaseInLeaseLiabilities	9364000	usd
CY2021	mgnx	Increase Decrease In Lease Liabilities IncreaseDecreaseInLeaseLiabilities	-3780000	usd
CY2023	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	11426000	usd
CY2022	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	48821000	usd
CY2021	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	9264000	usd
CY2023	mgnx	Increase Decrease In Deferred Rent IncreaseDecreaseInDeferredRent	0	usd
CY2022	mgnx	Increase Decrease In Deferred Rent IncreaseDecreaseInDeferredRent	0	usd
CY2021	mgnx	Increase Decrease In Deferred Rent IncreaseDecreaseInDeferredRent	258000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-78205000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-86959000	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-143830000	usd
CY2023	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	239683000	usd
CY2022	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	120602000	usd
CY2021	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	231208000	usd
CY2023	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	161299000	usd
CY2022	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	194940000	usd
CY2021	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	200800000	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1764000	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	3623000	usd
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	6201000	usd
CY2023	us-gaap	Proceeds From Sale Of Machinery And Equipment ProceedsFromSaleOfMachineryAndEquipment	64000	usd
CY2022	us-gaap	Proceeds From Sale Of Machinery And Equipment ProceedsFromSaleOfMachineryAndEquipment	0	usd
CY2021	us-gaap	Proceeds From Sale Of Machinery And Equipment ProceedsFromSaleOfMachineryAndEquipment	0	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-80084000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	70715000	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-36609000	usd
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	616000	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	1085000	usd
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	117818000	usd
CY2023	mgnx	Proceedsfrom Stock Options Exercised And Espp Purchases ProceedsfromStockOptionsExercisedAndESPPPurchases	553000	usd
CY2022	mgnx	Proceedsfrom Stock Options Exercised And Espp Purchases ProceedsfromStockOptionsExercisedAndESPPPurchases	574000	usd
CY2021	mgnx	Proceedsfrom Stock Options Exercised And Espp Purchases ProceedsfromStockOptionsExercisedAndESPPPurchases	4959000	usd
CY2023	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	306000	usd
CY2022	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	0	usd
CY2022	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	0	usd
CY2023	mgnx	Principal Payments On Royalty Monetization Arrangement PrincipalPaymentsOnRoyaltyMonetizationArrangement	157000	usd
CY2022	mgnx	Principal Payments On Royalty Monetization Arrangement PrincipalPaymentsOnRoyaltyMonetizationArrangement	0	usd
CY2021	mgnx	Principal Payments On Royalty Monetization Arrangement PrincipalPaymentsOnRoyaltyMonetizationArrangement	0	usd
CY2023	mgnx	Net Proceeds From Sale Of Future Royalties NetProceedsFromSaleOfFutureRoyalties	149655000	usd
CY2022	mgnx	Net Proceeds From Sale Of Future Royalties NetProceedsFromSaleOfFutureRoyalties	0	usd
CY2021	mgnx	Net Proceeds From Sale Of Future Royalties NetProceedsFromSaleOfFutureRoyalties	0	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	150361000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1659000	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	122777000	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-7928000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-14585000	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-57662000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	108884000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	123469000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	181131000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	100956000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	108884000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	123469000	usd
CY2023	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	505000	usd
CY2022	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	118000	usd
CY2021	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	508000	usd
CY2023Q4	us-gaap	Investments Investments	128800000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	46500000	usd
CY2022Q4	us-gaap	Investments Investments	45500000	usd
CY2023	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2023	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the financial statements in accordance with generally accepted accounting principles (GAAP) requires the Company to make estimates and judgments in certain circumstances that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. In preparing these consolidated financial statements, management has made its best estimates and judgments of certain amounts included in the financial statements, giving due consideration to materiality. On an ongoing basis, the Company evaluates its estimates, including those related to revenue recognition, fair values of assets, inventory, preclinical study and clinical trial accruals and other contingencies. Management bases its estimates on historical experience or on various other assumptions that it believes to be reasonable under the circumstances. Although actual results could differ from these estimates, management does not believe that such differences would be material.</span></div>
CY2023Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	91700000	usd
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash, cash equivalents, marketable securities and accounts receivable. </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains its cash and money market funds with financial institutions that are federally insured. While balances deposited in these institutions often exceed Federal Deposit Insurance Corporation limits, the Company has not experienced any losses on related accounts to date. The Company's investment policy limits investments to certain types of debt securities issued by the U.S. government, its agencies and institutions with investment-grade credit ratings and places restrictions on maturities and concentration by type and issuer.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The counterparties are various corporations, financial institutions and government agencies of high credit standing.</span></div>
CY2023Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	128855000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	16000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	22000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	128849000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	45467000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	6000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	11000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	45462000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0	usd
CY2023	us-gaap	Interest Income Other InterestIncomeOther	4000000	usd
CY2022	us-gaap	Interest Income Other InterestIncomeOther	1700000	usd
CY2021	us-gaap	Interest Income Other InterestIncomeOther	2000000	usd
CY2023Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	261000	usd
CY2022Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	409000	usd
CY2023Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	960000	usd
CY2022Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	1042000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	1221000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	1451000	usd
CY2023Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	3100000	usd
CY2022Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	4900000	usd
CY2023Q4	us-gaap	Construction In Progress Gross ConstructionInProgressGross	1112000	usd
CY2022Q4	us-gaap	Construction In Progress Gross ConstructionInProgressGross	356000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	110241000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	113660000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	88394000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	84085000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	21847000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	29575000	usd
CY2023	us-gaap	Depreciation Depreciation	9600000	usd
CY2022	us-gaap	Depreciation Depreciation	11900000	usd
CY2021	us-gaap	Depreciation Depreciation	11300000	usd
CY2023Q4	mgnx	Right Of Use Asset And Lease Liability Increase RightOfUseAssetAndLeaseLiabilityIncrease	14000000	usd
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P11Y
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P11Y1M6D
CY2023Q4	us-gaap	Lessee Operating Lease Discount Rate LesseeOperatingLeaseDiscountRate	0.120
CY2022Q4	us-gaap	Lessee Operating Lease Discount Rate LesseeOperatingLeaseDiscountRate	0.120
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	5900000	usd
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	6900000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	23800000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	27300000	usd
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	7459000	usd
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	5597000	usd
CY2023	us-gaap	Variable Lease Cost VariableLeaseCost	1316000	usd
CY2022	us-gaap	Variable Lease Cost VariableLeaseCost	1451000	usd
CY2023	us-gaap	Sublease Income SubleaseIncome	1109000	usd
CY2022	us-gaap	Sublease Income SubleaseIncome	1076000	usd
CY2023	us-gaap	Lease Cost LeaseCost	7666000	usd
CY2022	us-gaap	Lease Cost LeaseCost	5972000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	4004000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	5084000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	4209000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	4927000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	6049000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	46003000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	70276000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	36306000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	33970000	usd
CY2023Q3	mgnx	Gain On Royalty Monetization Arrangement GainOnRoyaltyMonetizationArrangement	50000000	usd
CY2023Q2	mgnx	Gain On Royalty Monetization Arrangement GainOnRoyaltyMonetizationArrangement	100900000	usd
CY2023Q3	mgnx	Gain On Royalty Monetization Arrangement GainOnRoyaltyMonetizationArrangement	50000000	usd
CY2022Q4	mgnx	Liability Related To Future Royalties LiabilityRelatedToFutureRoyalties	0	usd
CY2023	mgnx	Proceeds From Sale Of Future Royalties ProceedsFromSaleOfFutureRoyalties	150000000	usd
CY2023	mgnx	Deferred Transaction Costs DeferredTransactionCosts	343000	usd
CY2023	mgnx	Principal Payments On Royalty Monetization Arrangement PrincipalPaymentsOnRoyaltyMonetizationArrangement	157000	usd
CY2023	mgnx	Non Cash Interest Expense Recognized NonCashInterestExpenseRecognized	1430000	usd
CY2023	mgnx	Gain On Royalty Monetization Arrangement GainOnRoyaltyMonetizationArrangement	150930000	usd
CY2023Q4	mgnx	Liability Related To Future Royalties LiabilityRelatedToFutureRoyalties	0	usd
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	125000000	shares
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	18373000	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	20438000	usd
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	23126000	usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y10M17D
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y11M12D
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y3M
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	10098929	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	18.58
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y6M
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	3367777	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	4.97
CY2023	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	34608	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	3.73
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	365942	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	9.49
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	842519	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	19.12
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	12223637	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	15.11
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y8M12D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	16974000	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	7892753	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	18.92
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y7M6D
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	4509000	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	11346207	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	15.59
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P6Y6M
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	14692000	usd
CY2023	us-gaap	Stock Issued During Period Shares Share Based Compensation StockIssuedDuringPeriodSharesShareBasedCompensation	34608	shares
CY2022	us-gaap	Stock Issued During Period Shares Share Based Compensation StockIssuedDuringPeriodSharesShareBasedCompensation	120900	shares
CY2021	us-gaap	Stock Issued During Period Shares Share Based Compensation StockIssuedDuringPeriodSharesShareBasedCompensation	332767	shares
CY2023	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	100000	usd
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	200000	usd
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	5800000	usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	3.83
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	6.84
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	15.20
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	100000	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	600000	usd
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	3300000	usd
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	16400000	usd
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	19600000	usd
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	20200000	usd
CY2023Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	19500000	usd
CY2023	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y2M12D
CY2023	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	0	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	140706000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Domestic DeferredTaxAssetsOperatingLossCarryforwardsDomestic	163071000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	33350000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	44784000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	68251000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	65084000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Other DeferredTaxAssetsTaxCreditCarryforwardsOther	33330000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Other DeferredTaxAssetsTaxCreditCarryforwardsOther	35703000	usd
CY2023Q4	mgnx	Deferred Tax Assets Operating Lease Liabilities DeferredTaxAssetsOperatingLeaseLiabilities	9078000	usd
CY2022Q4	mgnx	Deferred Tax Assets Operating Lease Liabilities DeferredTaxAssetsOperatingLeaseLiabilities	9585000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	17442000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	0	usd
CY2023Q4	mgnx	Section174 Deferred Tax Asset Section174DeferredTaxAsset	48421000	usd
CY2022Q4	mgnx	Section174 Deferred Tax Asset Section174DeferredTaxAsset	43192000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	16217000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	15228000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	6617000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	4663000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	373412000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	381310000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	365010000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	372267000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	8402000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	9043000	usd
CY2023Q4	mgnx	Deferred Tax Liabilities Operating Lease Right Of Use Assets DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets	6372000	usd
CY2022Q4	mgnx	Deferred Tax Liabilities Operating Lease Right Of Use Assets DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets	7522000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Prepaid Expenses DeferredTaxLiabilitiesPrepaidExpenses	2030000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Prepaid Expenses DeferredTaxLiabilitiesPrepaidExpenses	1521000	usd
CY2023Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	8402000	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	9043000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	usd
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	372267000	usd
CY2023	mgnx	Valuation Allowance Deferred Tax Asset Increase Amount ValuationAllowanceDeferredTaxAssetIncreaseAmount	0	usd
CY2023	mgnx	Valuation Allowance Deferred Tax Asset Decrease Amount ValuationAllowanceDeferredTaxAssetDecreaseAmount	7257000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	365010000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	327592000	usd
CY2022	mgnx	Valuation Allowance Deferred Tax Asset Increase Amount ValuationAllowanceDeferredTaxAssetIncreaseAmount	44675000	usd
CY2022	mgnx	Valuation Allowance Deferred Tax Asset Decrease Amount ValuationAllowanceDeferredTaxAssetDecreaseAmount	0	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	372267000	usd
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	263400000	usd
CY2021	mgnx	Valuation Allowance Deferred Tax Asset Increase Amount ValuationAllowanceDeferredTaxAssetIncreaseAmount	64192000	usd
CY2021	mgnx	Valuation Allowance Deferred Tax Asset Decrease Amount ValuationAllowanceDeferredTaxAssetDecreaseAmount	0	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	327592000	usd
CY2023	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-1902000	usd
CY2022	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-25149000	usd
CY2021	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-42445000	usd
CY2023	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-163000	usd
CY2022	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-7385000	usd
CY2021	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-12806000	usd
CY2023	mgnx	Effective Income Tax Rate Reconciliation Deferred Tax Adjustments Amount EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount	5024000	usd
CY2022	mgnx	Effective Income Tax Rate Reconciliation Deferred Tax Adjustments Amount EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount	308000	usd
CY2021	mgnx	Effective Income Tax Rate Reconciliation Deferred Tax Adjustments Amount EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount	473000	usd
CY2023	mgnx	Effective Income Tax Rate Reconciliation Deferred State Blended Rate Adjustments Amount EffectiveIncomeTaxRateReconciliationDeferredStateBlendedRateAdjustmentsAmount	1841000	usd
CY2022	mgnx	Effective Income Tax Rate Reconciliation Deferred State Blended Rate Adjustments Amount EffectiveIncomeTaxRateReconciliationDeferredStateBlendedRateAdjustmentsAmount	0	usd
CY2021	mgnx	Effective Income Tax Rate Reconciliation Deferred State Blended Rate Adjustments Amount EffectiveIncomeTaxRateReconciliationDeferredStateBlendedRateAdjustmentsAmount	0	usd
CY2023	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	3168000	usd
CY2022	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	4569000	usd
CY2021	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	10243000	usd
CY2023	mgnx	Effective Income Tax Rate Reconciliation Tax Credit Orphan Drug Amount EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugAmount	-2374000	usd
CY2022	mgnx	Effective Income Tax Rate Reconciliation Tax Credit Orphan Drug Amount EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugAmount	10846000	usd
CY2021	mgnx	Effective Income Tax Rate Reconciliation Tax Credit Orphan Drug Amount EffectiveIncomeTaxRateReconciliationTaxCreditOrphanDrugAmount	1449000	usd
CY2023	us-gaap	Income Tax Reconciliation Other Reconciling Items IncomeTaxReconciliationOtherReconcilingItems	1301000	usd
CY2022	us-gaap	Income Tax Reconciliation Other Reconciling Items IncomeTaxReconciliationOtherReconcilingItems	1362000	usd
CY2021	us-gaap	Income Tax Reconciliation Other Reconciling Items IncomeTaxReconciliationOtherReconcilingItems	1199000	usd
CY2023	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	1950000	usd
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	1604000	usd
CY2021	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	1079000	usd
CY2023	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-7257000	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	44675000	usd
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	64192000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	7376000	usd
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	7197000	usd
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	6126000	usd
CY2023	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	449000	usd
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	548000	usd
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	965000	usd
CY2023	mgnx	Unrecognized Tax Benefits Increase Decrease Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions	-4000	usd
CY2022	mgnx	Unrecognized Tax Benefits Increase Decrease Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions	-369000	usd
CY2021	mgnx	Unrecognized Tax Benefits Increase Decrease Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions	106000	usd
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	7821000	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	7376000	usd
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	7197000	usd
CY2023Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	7800000	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	7400000	usd
CY2021	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0	usd
CY2022	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0	usd
CY2023	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0	usd
CY2023	mgnx	Employees Eligible Age To Participate In Benefit Plan EmployeesEligibleAgeToParticipateInBenefitPlan	P21Y
CY2023	us-gaap	Defined Contribution Plan Maximum Annual Contributions Per Employee Percent DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent	1
CY2023	mgnx	Defined Contribution Plan Employees Contribution Vested Percentage DefinedContributionPlanEmployeesContributionVestedPercentage	1
CY2023	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	2100000	usd
CY2022	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	2300000	usd
CY2021	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	1600000	usd

Files In Submission

Name	View Source	Status
0001125345-24-000060-index-headers.html	Edgar Link	pending
0001125345-24-000060-index.html	Edgar Link	pending
0001125345-24-000060.txt	Edgar Link	pending
0001125345-24-000060-xbrl.zip	Edgar Link	pending
exhibit1010bodoptiongrantn.htm	Edgar Link	pending
exhibit1011bodrsuawardgran.htm	Edgar Link	pending
exhibit108employeestockopt.htm	Edgar Link	pending
exhibit109employeersuaward.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
mgnx-20231231.htm	Edgar Link	pending
mgnx-20231231.xsd	Edgar Link	pending
mgnx-20231231_g1.jpg	Edgar Link	pending
mgnx-20231231_g2.jpg	Edgar Link	pending
mgnx-20231231_g3.jpg	Edgar Link	pending
mgnxex97-1clawbackpolicy.htm	Edgar Link	pending
mgnxexhibit23-1202310xk.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
mgnx-20231231_cal.xml	Edgar Link	unprocessable
mgnx-20231231_def.xml	Edgar Link	unprocessable
mgnx-20231231_lab.xml	Edgar Link	unprocessable
mgnx-20231231_pre.xml	Edgar Link	unprocessable
mgnx-20231231_htm.xml	Edgar Link	completed
mgnxexhibit31-1202310xk.htm	Edgar Link	pending
mgnxexhibit31-2202310xk.htm	Edgar Link	pending
mgnxexhibit32-1202310xk.htm	Edgar Link	pending
mgnxexhibit32-2202310xk.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$MGNX
MACROGENICS INC Stock $mgnx

2024 Q1 Form 10-K Financial Statement

#000112534524000060 Filed on March 07, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MGNX MACROGENICS INC Stock $mgnx

2024 Q1 Form 10-K Financial Statement

#000112534524000060 Filed on March 07, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MGNX
MACROGENICS INC Stock $mgnx